Logo - springer
Slogan - springer

Birkhäuser - Birkhäuser BioSciences | Recombinant Protein Drugs

Recombinant Protein Drugs

Buckel, P. (Ed.)

2001, X, 207 p.

A product of Birkhäuser Basel
Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$129.00

(net) price for USA

ISBN 978-3-0348-8346-7

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$289.00

(net) price for USA

ISBN 978-3-7643-5904-1

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$169.00

(net) price for USA

ISBN 978-3-0348-9527-9

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Recombinant protein drugs are intimately associated with the impressive success story of the Biotech Industry during the past thirty years, some of them belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early Biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss...

Content Level » Professional/practitioner

Keywords » clinic - clinical trial - development - drug - drug discovery - drugs - future - gene therapy - hepatitis - interferon - oncology - pharmaceutical - protein - protein engineering - research

Related subjects » Birkhäuser BioSciences

Table of contents 

Pioneers and business.- Recombinant interferon — the 20th anniversary.- Combining science and business: from recombinant DNA to vaccines against hepatitis B virus.- First generation proteins.- Clotting factors VIII and IX.- Colony-stimulating factors: altering the practice of oncology.- Tissue-type plasminogen activator: helping patients with acute myocardial infarction.- Proteins with new functions: protein engineering.- Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy.- Further improvement of protein drugs.- Improving protein therapeutics: the evolution of the modern pharmacopoeia.- Principles of gene transfer and foreign protein expression for human gene therapy.- Short biographies.- List of approved “recombinant protein drugs”.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Medicine (general).